235 related articles for article (PubMed ID: 34880698)
1. Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer.
Brazel D; Nagasaka M
Lung Cancer (Auckl); 2021; 12():133-138. PubMed ID: 34880698
[TBL] [Abstract][Full Text] [Related]
2. The development of amivantamab for the treatment of non-small cell lung cancer.
Brazel D; Nagasaka M
Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
[TBL] [Abstract][Full Text] [Related]
3. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on Mobocertinib (TAK-788) in NSCLC with
Zhang SS; Zhu VW
Lung Cancer (Auckl); 2021; 12():61-65. PubMed ID: 34285620
[TBL] [Abstract][Full Text] [Related]
5. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
Petrini I; Giaccone G
Onco Targets Ther; 2022; 15():1197-1210. PubMed ID: 36246734
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
7. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Chon K; Larkins E; Chatterjee S; Mishra-Kalyani PS; Aungst S; Wearne E; Subramaniam S; Li Y; Liu J; Sun J; Charlab R; Zhao H; Saritas-Yildirim B; Bikkavilli RK; Ghosh S; Philip R; Beaver JA; Singh H
Clin Cancer Res; 2023 Sep; 29(17):3262-3266. PubMed ID: 37022784
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of non-small-cell lung cancer harbouring
Low JL; Lim SM; Lee JB; Cho BC; Soo RA
Ther Adv Med Oncol; 2023; 15():17588359221146131. PubMed ID: 36756143
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
[TBL] [Abstract][Full Text] [Related]
12. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.
Cho BC; Simi A; Sabari J; Vijayaraghavan S; Moores S; Spira A
Clin Lung Cancer; 2023 Mar; 24(2):89-97. PubMed ID: 36481319
[TBL] [Abstract][Full Text] [Related]
13. Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines.
Olivier T; Prasad V
Transl Oncol; 2022 Sep; 23():101475. PubMed ID: 35785671
[TBL] [Abstract][Full Text] [Related]
14. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
16.
Sentana-Lledo D; Academia E; Viray H; Rangachari D; Kobayashi SS; VanderLaan PA; Costa DB
Transl Lung Cancer Res; 2023 Jul; 12(7):1590-1610. PubMed ID: 37577308
[TBL] [Abstract][Full Text] [Related]
17. Treatment of uncommon
Zhang T; Wan B; Zhao Y; Li C; Liu H; Lv T; Zhan P; Song Y
Transl Lung Cancer Res; 2019 Jun; 8(3):302-316. PubMed ID: 31367543
[TBL] [Abstract][Full Text] [Related]
18. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Shah V; McNatty A; Simpson L; Ofori H; Raheem F
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
[TBL] [Abstract][Full Text] [Related]
19. Amivantamab for the treatment of
Vyse S; Huang PH
Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
